History of infantile BCG immunization did not predict lamina propria invasion and/or high-grade in patients with non-muscle invasive bladder cancer

Anastasia MacDonald; Vahid Mehrnoush; Asmaa Ismail; Livio Di Matteo; Ahmed Zakaria; Waleed Shabana; Ashraf Shaban; Mohammed Bassuony; Hazem Elmansy; Walid Shahrour; Owen Prowse; Ahmed Kotb

doi:10.4081/aiua.2023.11380

Authors

Anastasia MacDonald Northern Ontario School of Medicine, Thunder Bay, ON, Canada. https://orcid.org/0009-0006-4756-3742
Vahid Mehrnoush Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Asmaa Ismail Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Livio Di Matteo Department of Economics, Lakehead University, Thunder Bay, ON, Canada.
Ahmed Zakaria Northern Ontario School of Medicine, Thunder Bay, ON, Canada. https://orcid.org/0000-0002-4582-9969
Waleed Shabana Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Ashraf Shaban Northern Ontario School of Medicine, Thunder Bay, ON, Canada. https://orcid.org/0009-0003-6647-0136
Mohammed Bassuony Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Hazem Elmansy Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Walid Shahrour Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Owen Prowse Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
Ahmed Kotb
drahmedfali@gmail.com
Northern Ontario School of Medicine, Thunder Bay, ON, Canada. https://orcid.org/0000-0002-1484-1332

Objective: To evaluate the utility of infantile BCG vaccination history in predicting stage and grade of tumours in non-muscle invasive bladder cancer (NMIBC). Materials and methods: We retrospectively analyzed data from patients from a single center who were diagnosed with new NMIBC and underwent transurethral resection of bladder tumour (TURBT) between 2017 and 2022. We assessed BCG immunization status with various demographics and comorbidities, as well as tumour recurrence, progression, stage, and grade. Results: A total of 188 patients met the inclusion criteria for our study. The mean age of patients at the time of diagnosis was significantly lower in those that had been immunized with BCG (71 ± 9) than those who had not (77 ± 10) (p < 0.0001). History of BCG immunization did not correlate with sex, history of diabetes mellitus (DM), prior history of intravesical BCG treatment, and tumour recurrence, progression, stage, and grade. Conclusions: History of infantile BCG vaccination did not correlate with the depth of invasion and/or the grade in patients with non-muscle invasive bladder cancer. Patients that received infantile BCG vaccination were significantly younger at the time of diagnosis of NMIBC.

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 2018; 68:394. DOI: https://doi.org/10.3322/caac.21492

Mushtaq J, Thurairaja R, Nair, R. Bladder cancer Surgery (Oxf). 2019; 37:529. DOI: https://doi.org/10.1016/j.mpsur.2019.07.003

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019 CA Cancer J Clin. 2019; 69:7. DOI: https://doi.org/10.3322/caac.21551

Saginala K, Barsouk A, Aluru JS, et al. Epidemiology of Bladder Cancer Med Sci. 2020; 8:15. DOI: https://doi.org/10.3390/medsci8010015

Taniguchi K, Koga S, Nishikido M, et al. Systemic immune response after intravesical instillation of Bacille Calmette-Guérin (BCG) for superficial bladder cancer Clin Exp Immunol. 1999; 115:131. DOI: https://doi.org/10.1046/j.1365-2249.1999.00756.x

Trigo S, Gonzalez K, Di Matteo L, et al. Bacillus Calmette-Guerin vaccine and bladder cancer incidence: Scoping literature review and preliminary analysis Arch Ital Urol. 2021; 93:1. DOI: https://doi.org/10.4081/aiua.2021.1.1

Mukherjee N, Julián E, Torrelles JB, Svatek RS. Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond Vaccine. 2021; 39:7332. DOI: https://doi.org/10.1016/j.vaccine.2021.09.053

Covián C, Fernández-Fierro A, Retamal-Díaz A, et al. BCGInduced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design Front Immunol. 2019; 10:2806. DOI: https://doi.org/10.3389/fimmu.2019.02806

van Puffelen J H, Novakovic B, van Emst L, et al. Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections J Immunother Cancer. 2023; 11:e005518. DOI: https://doi.org/10.1136/jitc-2022-005518

Martinez L, Cords O, Liu Q, et al. Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data metaanalysis Lancet Glob Health. 2022: 10:e1307.

Niwa N, Kikuchi E, Matsumoto K, et al. Purified protein derivative skin test reactions are associated with clinical outcomes of patients with nonmuscle invasive bladder cancer treated with induction bacillus Calmette-Guérin therapy Urol Oncol. 2018; 36e15. DOI: https://doi.org/10.1016/j.urolonc.2017.10.005

Biot C, Rentsch CA, Gsponer JR, et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer Sci Transl Med. 2012; 4:72. DOI: https://doi.org/10.1126/scitranslmed.3003586

Centers for Disease Control and Prevention. BCG Vaccine Fact Sheet. 2016. Retrieved from https://www.cdc.gov/tb/publications/factsheets/prevention/bcg.htm

MacDonald, A., Mehrnoush, V., Ismail, A., Di Matteo, L., Zakaria, A., Shabana, W., Shaban, A., Bassuony, M., Elmansy, H., Shahrour, W., Prowse, O., & Kotb, A. (2023). History of infantile BCG immunization did not predict lamina propria invasion and/or high-grade in patients with non-muscle invasive bladder cancer. Archivio Italiano Di Urologia E Andrologia, 95(2). https://doi.org/10.4081/aiua.2023.11380